Drug maker Alumis (ALMS) is climbing 7% after investment bank Oppenheimer started coverage of the name with an Outperform ...

Type a few symbols and Take a Trial. The signals for these will appear immediately on your My Stocks Page; add more too.

Alumis (NASDAQ:ALMS – Get Free Report) is expected to issue its quarterly earnings data before the market opens on Wednesday, February 12th. Analysts expect the company to announce earnings of ($1.36) ...

In a report released today, Jeff Jones from Oppenheimer reiterated a Buy rating on Alumis Inc. (ALMS – Research Report), with a price target of ...

Indore has recently issued an order to make the city beggar-free. The order directs action against not only beggars but also ...

Halper Sadeh LLC, an investor rights law firm, is investigating whether the merger of Alumis Inc. (NASDAQ: ALMS) and ACELYRIN ...

Several beggars, seeking alms at traffic signals, have been found involved in criminal activities and drug-addiction. Their ...

Several beggars, seeking alms at traffic signals, have been found involved in criminal activities and drug-addiction.

There’s a lot to be optimistic about in the Materials sector as 2 analysts just weighed in on Alumis Inc. (ALMS – Research Report) and Martin ...

Bhopal: Authorities have banned begging in Madhya Pradesh capital Bhopal and warned of penal action against those found ...

Fintel reports that on January 30, 2025, Oppenheimer initiated coverage of Alumis (NasdaqGS:ALMS) with a Outperform ...

Drug maker Alumis (ALMS) is climbing 7% after investment bank Oppenheimer started coverage of the name with an Outperform rating. Why Oppenheimer Is Bullish on ALMS Due to concerns about Alumis ...